Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

OTHER 1

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Renal Insufficiency 1Osteosarcoma 1Neoplasms 1Lymphoma 1Leukemia 1

Interventions

fludarabine phosphate 2tisagenlecleucel 1revumenib 1ponatinib 1midostaurin 1immunotoxin HA22 1glucarpidase 1fludarabine 1Whole-Body Irradiation 1Tacrolimus 1Mycophenolic Acid 1HA 22 1Cytarabine 1Cyclophosphamide 1Cord Blood Stem Cell Transplantation 1Carboxypeptidases 1Busulfan 1Bone Marrow Transplantation 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Leukemia × glucarpidase × Clear all
NCT00481559 2014-01-17

Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity

BTG International Inc.

Approved for marketing
LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neoplasms, Osteosarcoma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡